Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...

Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...